Sputnik V vaccine has 91.6% efficacy against symptomatic Covid, Russian trial suggests

Preliminary findings based on analysis of data from more than 20,000 participants

• Coronavirus - latest updates
• See all our coronavirus coverage

The Sputnik V vaccine, which has been the subject of scepticism since Russia began using it last year before trials had ended, is 91.6% effective against symptomatic Covid according to data published in one of the world's leading medical journals.

Results in the Lancet from 20,000 trial participants suggest Sputnik's efficacy is on a par with that of some of the leading vaccines now in use. There was good efficacy in older adults, who are at highest risk for death, but little diversity, since most participants were white males.